Tìm theo
Lumefantrine
Các tên gọi khác (6 ) :
  • (+-)-2,7-Dichloro-9-((Z)-P-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
  • 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
  • 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
  • Benflumetol
  • DL-Benflumelol
  • Lumefantrine
antimalarials
Thuốc Gốc
Small Molecule
CAS: 82186-77-4
ATC: P01BF01
CTHH: C30H32Cl3NO
PTK: 528.94
Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C30H32Cl3NO
Phân tử khối
528.94
Monoisotopic mass
527.154947772
InChI
InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
InChI Key
InChIKey=DYLGFOYVTXJFJP-MYYYXRDXSA-N
IUPAC Name
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol
Traditional IUPAC Name
lumefantrine
SMILES
CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1
Độ hòa tan
3.09e-05 g/l
logP
9.19
logS
-7.2
pKa (strongest acidic)
14.1
pKa (Strongest Basic)
9.78
PSA
23.47 Å2
Refractivity
160.81 m3·mol-1
Polarizability
60.69 Å3
Rotatable Bond Count
10
H Bond Acceptor Count
2
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
4
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Lumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. It is thought that administration of lumefantrine with artemether results in cooperate antimalarial clearing effects. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thus thought to provide rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
Cơ Chế Tác Dụng : Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas. The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis.
Dược Động Học :
▧ Absorption :
Food increases absorption.
▧ Protein binding :
99.7% bound
▧ Metabolism :
Extensively metabolized in the liver primarily by cytochrome P450 3A4. The major metabolite found in plasma is desbutyl-lumefantrine.
▧ Half Life :
~ 4.5 days
Độc Tính : Common side effects of combination artemether/lumefantrine therapy in adults include headache, anorexia, dizziness, and asthenia. Common side effects in children include pyrexia, cough, vomiting, anorexia, and headache. Possible serious adverse effects include QT prolongation, bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 9%; children, 6%), hypersensitivty reaction, and angioedema.
Chỉ Định : Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
Tương Tác Thuốc :
  • Amiodarone Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Amitriptyline Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Amoxapine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Apomorphine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Arsenic trioxide Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Asenapine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Azithromycin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Bepridil Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Chloroquine Chloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Chlorpromazine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Cisapride Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Citalopram Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Dapsone Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions.
  • Doxepin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Dronedarone Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
  • Droperidol Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Erythromycin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Escitalopram Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Flecainide Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Fluconazole Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Fluoxetine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Flupentixol Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Foscarnet Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Gadobutrol Additive QTc-prolongation may occur. Consider alternate therapy or monitor closely for QTc-prolongation.
  • Gadofosveset trisodium Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Halofantrine Halofantrine may increase the adverse effects of lumefantrine. Additive QTc-prolongation may occur. Combination therapy is contraindicated and therapies should not be administered within one month of each other due to the long half-life of lumefantrine.
  • Haloperidol Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Hydroxychloroquine Hydroxychloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Ibutilide Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Iloperidone Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Imipramine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Indapamide Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Isradipine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Lapatinib Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Levofloxacin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Loxapine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Maprotiline Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Mefloquine Mefloquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Mesoridazine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Methadone Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Methotrimeprazine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Moxifloxacin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Nilotinib Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Norfloxacin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Nortriptyline Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Octreotide Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Pazopanib Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Pentamidine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Perflutren Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Pimozide Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
  • Primaquine Primaquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Probucol Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Procainamide Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Proguanil Proguanil may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Propafenone Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Protriptyline Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Pyrimethamine Pyrimethamine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Quetiapine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Quinidine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Quinine Quinine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options.
  • Ranolazine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Risperidone Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Romidepsin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Sotalol Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Sparfloxacin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Sunitinib Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Tacrolimus Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Tamoxifen Lumefantrine, a moderate CYP2D6 inhibitor, may decrease the formation of highly potent tamoxifen metabolites. Concomitant therapy may decrease the effectiveness of tamoxifen. Consider alternate therapy.
  • Telavancin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Telithromycin Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Tetrabenazine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Thioridazine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Thiothixene Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Toremifene Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Trimipramine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Voriconazole Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Vorinostat Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Ziprasidone Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Zuclopenthixol Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Liều Lượng & Cách Dùng : Tablet - Oral - 20 mg artemether and 120 mg lumefantrine
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06708
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=6437380
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=99443260
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D03821
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50123012
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0078-0568-45
PharmGKB
http://www.pharmgkb.org/drug/PA165111722
Wikipedia
http://en.wikipedia.org/wiki/Lumefantrine
RxList
http://www.rxlist.com/coartem-drug.htm
Drugs.com
http://www.drugs.com/pro/coartem.html
... loading
... loading